Evidence library

Will I lose muscle on a GLP-1?

Some of the weight you lose on these drugs is lean tissue, not fat. Here's what the evidence actually says about how much, whether it matters, and what, if anything, holds onto muscle.

How to read these grades

Evidence strength

  • Strong evidence (does / reduces / improves)
  • Moderate evidence (probably / likely)
  • Early / weak evidence (may / might)

Tested in GLP-1 users?

  • Tested in GLP-1 users
  • Not tested in GLP-1 users
  • Trial underway

Some of the weight you lose is muscle, not just fat

Strong evidence Tested in GLP-1 users

Body-scan studies of people on GLP-1s show lean mass falls alongside fat. This is measured directly in the people taking these drugs, not extrapolated from anyone else.

What it rests on

  • SURMOUNT-1 DXA substudy 1

    A substudy of the large tirzepatide obesity trial used body scans to see what kind of weight people lost over 72 weeks. Both fat and lean tissue came down, but fat made up the clear majority of the loss.

    Tirzepatide, 72 weeks

  • STEP-1 body-composition 2

    A body-composition analysis of the semaglutide 2.4 mg trial. Lean mass dropped in absolute terms, yet as a share of total body weight it slightly rose, meaning fat was lost faster than lean tissue.

    Semaglutide 2.4 mg

The scary "half your weight loss is muscle" stat is a reframe, not a finding

Moderate evidence Tested in GLP-1 users

Read directly, the body-scan data are less alarming than the headlines. Lean mass falls, but not disproportionately, and the widely quoted "40% of weight lost was muscle" is a kilogram calculation, not something the studies measured. The real muscle share is closer to 1 in 5.

What it rests on

  • STEP-1 body-composition 2

    A body-composition analysis of the semaglutide 2.4 mg trial. Lean mass dropped in absolute terms, yet as a share of total body weight it slightly rose, meaning fat was lost faster than lean tissue.

    Semaglutide 2.4 mg

Strength training is the most reliable way to keep muscle while losing weight

Strong evidence Not tested in GLP-1 users

Resistance training reliably preserves lean mass during weight loss, and aerobic exercise alone does less. The evidence base is strong, but it comes from dieters and older adults, not yet from large trials in people on GLP-1s.

What it rests on

  • Eglseer 2023 3

    A pooled analysis of many diet and exercise trials in adults near retirement age. Resistance or combined training held onto more lean mass than dieting alone or aerobic exercise alone.

    Dieters and older adults, not GLP-1

  • Sardeli 2018 4

    A pooled analysis of trials in older adults cutting calories to lose weight. Adding resistance training largely prevented the muscle loss that dieting on its own produced.

    Caloric restriction, not GLP-1

What would change this grade

LEAN-PREP (NCT06885736) is testing resistance training plus protein during semaglutide or tirzepatide. When it reports, this grade may move to "tested in GLP-1 users".

With training and enough protein, some people keep or even build muscle on these drugs

Early / weak evidence Tested in GLP-1 users

Early real-world data suggest people who resistance-train and eat enough protein can preserve, sometimes gain, lean tissue and strength while on GLP-1s. This is a proof of concept, not a typical result. The best data here is a 3-person case series.

What it rests on

  • Lean-tissue case series 5

    A report on three people losing weight on GLP-1 drugs while lifting weights and eating high protein. Two of the three gained lean tissue, which shows preservation is possible, though three people cannot tell us how often it happens.

    GLP-1 users, n=3

  • SEMALEAN cohort 6

    An uncontrolled study that followed people on semaglutide for a year. Grip strength improved and fewer people met the definition of low-muscle obesity, but with no comparison group the drug cannot take sole credit.

    GLP-1 users, uncontrolled

Protein alone is not enough without resistance training

Expert consensus Mixed / consensus

Clinicians emphasize that higher protein intake on its own is probably not enough to protect muscle without structured strength training. This is expert consensus from a four-society advisory, not a single trial.

What it rests on

  • Mozaffarian 2025 advisory 7

    A joint advisory from four medical societies summarizing current best practice for supporting people on GLP-1s. It is an expert consensus document, not a trial, and is the standard reference for what the field recommends and where evidence is still missing.

    Four-society expert consensus

Sources

  1. 1. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obesity Metabolism. 2025;27(5):2720-2729. doi:10.1111/dom.16275
  2. 2. Wilding JPH, Batterham RL, Calanna S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society. 2021;5(Supplement_1):A16-A17. doi:10.1210/jendso/bvab048.030
  3. 3. Eglseer D, Traxler M, Embacher S, et al. Nutrition and Exercise Interventions to Improve Body Composition for Persons with Overweight or Obesity Near Retirement Age: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Advances in Nutrition. 2023;14(3):516-538. doi:10.1016/j.advnut.2023.04.001
  4. 4. Sardeli AV, Komatsu TR, Mori MA, Gáspari AF, Chacon-Mikahil MPT. Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Nutrients. 2018;10(4):423. doi:10.3390/nu10040423
  5. 5. Tinsley GM, Nadolsky S. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. SAGE Open Medical Case Reports. 2025;13. doi:10.1177/2050313x251388724
  6. 6. Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obesity Metabolism. 2026;28(1):112-121. doi:10.1111/dom.70141
  7. 7. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023